CYP1A1 T3801 C polymorphism and lung cancer: A pooled analysis of 2,451 cases and 3,358 controls

Paolo Vineis, Fabrizio Veglia, Simone Benhamou, Dorota Butkiewicz, Ingolf Cascorbi, Margie L. Clapper, Vita Dolzan, Aage Haugen, Ari Hirvonen, Magnus Ingelman-Sundberg, Masahiro Kihara, Chikako Kiyohara, Pierre Kremers, Loic Le Marchand, Susumu Ohshima, Roberta Pastorelli, Agneta Rannug, Marjorie Romkes, B. Schoket, Peter ShieldsRichard C. Strange, Isabelle Stucker, Haruhiko Sugimura, Seymour Garte, Laura Gaspari, Emanuela Taioli

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

CYP1A1 is involved in the metabolism of benzopyrene, a suspected lung carcinogen; it is therefore conceivable that genetically determined variations in its activity modify individual susceptibility to lung cancer. The role of the CYP1A1 MspI polymorphism in lung cancer has been widely studied but has not been fully clarified. We have included 2,451 cases and 3,358 controls in a pooled analysis of 22 case-control studies on CYP1A1 and lung cancer risk. We found a clear association between the CYP1A1 homozygous MspI restriction fragment length polymorphism (RFLP) and lung cancer risk in Caucasians (age- and gender-adjusted odds ratio = 2.36; 95% confidence interval 1.16-4.81); other associations were weaker or not statistically significant. The association with the homozygous variant was equally strong for squamous cell carcinomas and adenocarcinomas among Caucasians. We analyzed the risk by duration of smoking: for Caucasian subjects with the MspI RFLP combined variants (homozygotes plus heterozygotes), the increase in the risk of lung cancer was steeper than among the individuals with the homozygous reference allele. Our analysis suggests that Caucasians with homozygous variant CYP1A1 polymorphism have a higher risk of lung cancer. The data were more consistent among Caucasians, with a strong association between the homozygous variant in both squamous cell carcinomas and adenocarcinomas, and a stronger association in men than in women. The analyses were more inconsistent and failed to reach statistical significance in Asians. This observation might be due to design specificities or unknown effect modifiers in the Asian studies.

Original languageEnglish
Pages (from-to)650-657
Number of pages8
JournalInternational Journal of Cancer
Volume104
Issue number5
DOIs
Publication statusPublished - May 1 2003

Fingerprint

Cytochrome P-450 CYP1A1
Lung Neoplasms
Restriction Fragment Length Polymorphisms
Squamous Cell Carcinoma
Adenocarcinoma
Benzopyrenes
Homozygote
Heterozygote
Carcinogens
Case-Control Studies
Smoking
Alleles
Odds Ratio
Confidence Intervals
Lung

Keywords

  • CYP1A1TC polymorphism
  • Lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Vineis, P., Veglia, F., Benhamou, S., Butkiewicz, D., Cascorbi, I., Clapper, M. L., ... Taioli, E. (2003). CYP1A1 T3801 C polymorphism and lung cancer: A pooled analysis of 2,451 cases and 3,358 controls. International Journal of Cancer, 104(5), 650-657. https://doi.org/10.1002/ijc.10995

CYP1A1 T3801 C polymorphism and lung cancer : A pooled analysis of 2,451 cases and 3,358 controls. / Vineis, Paolo; Veglia, Fabrizio; Benhamou, Simone; Butkiewicz, Dorota; Cascorbi, Ingolf; Clapper, Margie L.; Dolzan, Vita; Haugen, Aage; Hirvonen, Ari; Ingelman-Sundberg, Magnus; Kihara, Masahiro; Kiyohara, Chikako; Kremers, Pierre; Le Marchand, Loic; Ohshima, Susumu; Pastorelli, Roberta; Rannug, Agneta; Romkes, Marjorie; Schoket, B.; Shields, Peter; Strange, Richard C.; Stucker, Isabelle; Sugimura, Haruhiko; Garte, Seymour; Gaspari, Laura; Taioli, Emanuela.

In: International Journal of Cancer, Vol. 104, No. 5, 01.05.2003, p. 650-657.

Research output: Contribution to journalArticle

Vineis, P, Veglia, F, Benhamou, S, Butkiewicz, D, Cascorbi, I, Clapper, ML, Dolzan, V, Haugen, A, Hirvonen, A, Ingelman-Sundberg, M, Kihara, M, Kiyohara, C, Kremers, P, Le Marchand, L, Ohshima, S, Pastorelli, R, Rannug, A, Romkes, M, Schoket, B, Shields, P, Strange, RC, Stucker, I, Sugimura, H, Garte, S, Gaspari, L & Taioli, E 2003, 'CYP1A1 T3801 C polymorphism and lung cancer: A pooled analysis of 2,451 cases and 3,358 controls', International Journal of Cancer, vol. 104, no. 5, pp. 650-657. https://doi.org/10.1002/ijc.10995
Vineis P, Veglia F, Benhamou S, Butkiewicz D, Cascorbi I, Clapper ML et al. CYP1A1 T3801 C polymorphism and lung cancer: A pooled analysis of 2,451 cases and 3,358 controls. International Journal of Cancer. 2003 May 1;104(5):650-657. https://doi.org/10.1002/ijc.10995
Vineis, Paolo ; Veglia, Fabrizio ; Benhamou, Simone ; Butkiewicz, Dorota ; Cascorbi, Ingolf ; Clapper, Margie L. ; Dolzan, Vita ; Haugen, Aage ; Hirvonen, Ari ; Ingelman-Sundberg, Magnus ; Kihara, Masahiro ; Kiyohara, Chikako ; Kremers, Pierre ; Le Marchand, Loic ; Ohshima, Susumu ; Pastorelli, Roberta ; Rannug, Agneta ; Romkes, Marjorie ; Schoket, B. ; Shields, Peter ; Strange, Richard C. ; Stucker, Isabelle ; Sugimura, Haruhiko ; Garte, Seymour ; Gaspari, Laura ; Taioli, Emanuela. / CYP1A1 T3801 C polymorphism and lung cancer : A pooled analysis of 2,451 cases and 3,358 controls. In: International Journal of Cancer. 2003 ; Vol. 104, No. 5. pp. 650-657.
@article{28bfaeb66803427cba3fac1e37d0750b,
title = "CYP1A1 T3801 C polymorphism and lung cancer: A pooled analysis of 2,451 cases and 3,358 controls",
abstract = "CYP1A1 is involved in the metabolism of benzopyrene, a suspected lung carcinogen; it is therefore conceivable that genetically determined variations in its activity modify individual susceptibility to lung cancer. The role of the CYP1A1 MspI polymorphism in lung cancer has been widely studied but has not been fully clarified. We have included 2,451 cases and 3,358 controls in a pooled analysis of 22 case-control studies on CYP1A1 and lung cancer risk. We found a clear association between the CYP1A1 homozygous MspI restriction fragment length polymorphism (RFLP) and lung cancer risk in Caucasians (age- and gender-adjusted odds ratio = 2.36; 95{\%} confidence interval 1.16-4.81); other associations were weaker or not statistically significant. The association with the homozygous variant was equally strong for squamous cell carcinomas and adenocarcinomas among Caucasians. We analyzed the risk by duration of smoking: for Caucasian subjects with the MspI RFLP combined variants (homozygotes plus heterozygotes), the increase in the risk of lung cancer was steeper than among the individuals with the homozygous reference allele. Our analysis suggests that Caucasians with homozygous variant CYP1A1 polymorphism have a higher risk of lung cancer. The data were more consistent among Caucasians, with a strong association between the homozygous variant in both squamous cell carcinomas and adenocarcinomas, and a stronger association in men than in women. The analyses were more inconsistent and failed to reach statistical significance in Asians. This observation might be due to design specificities or unknown effect modifiers in the Asian studies.",
keywords = "CYP1A1TC polymorphism, Lung cancer",
author = "Paolo Vineis and Fabrizio Veglia and Simone Benhamou and Dorota Butkiewicz and Ingolf Cascorbi and Clapper, {Margie L.} and Vita Dolzan and Aage Haugen and Ari Hirvonen and Magnus Ingelman-Sundberg and Masahiro Kihara and Chikako Kiyohara and Pierre Kremers and {Le Marchand}, Loic and Susumu Ohshima and Roberta Pastorelli and Agneta Rannug and Marjorie Romkes and B. Schoket and Peter Shields and Strange, {Richard C.} and Isabelle Stucker and Haruhiko Sugimura and Seymour Garte and Laura Gaspari and Emanuela Taioli",
year = "2003",
month = "5",
day = "1",
doi = "10.1002/ijc.10995",
language = "English",
volume = "104",
pages = "650--657",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - CYP1A1 T3801 C polymorphism and lung cancer

T2 - A pooled analysis of 2,451 cases and 3,358 controls

AU - Vineis, Paolo

AU - Veglia, Fabrizio

AU - Benhamou, Simone

AU - Butkiewicz, Dorota

AU - Cascorbi, Ingolf

AU - Clapper, Margie L.

AU - Dolzan, Vita

AU - Haugen, Aage

AU - Hirvonen, Ari

AU - Ingelman-Sundberg, Magnus

AU - Kihara, Masahiro

AU - Kiyohara, Chikako

AU - Kremers, Pierre

AU - Le Marchand, Loic

AU - Ohshima, Susumu

AU - Pastorelli, Roberta

AU - Rannug, Agneta

AU - Romkes, Marjorie

AU - Schoket, B.

AU - Shields, Peter

AU - Strange, Richard C.

AU - Stucker, Isabelle

AU - Sugimura, Haruhiko

AU - Garte, Seymour

AU - Gaspari, Laura

AU - Taioli, Emanuela

PY - 2003/5/1

Y1 - 2003/5/1

N2 - CYP1A1 is involved in the metabolism of benzopyrene, a suspected lung carcinogen; it is therefore conceivable that genetically determined variations in its activity modify individual susceptibility to lung cancer. The role of the CYP1A1 MspI polymorphism in lung cancer has been widely studied but has not been fully clarified. We have included 2,451 cases and 3,358 controls in a pooled analysis of 22 case-control studies on CYP1A1 and lung cancer risk. We found a clear association between the CYP1A1 homozygous MspI restriction fragment length polymorphism (RFLP) and lung cancer risk in Caucasians (age- and gender-adjusted odds ratio = 2.36; 95% confidence interval 1.16-4.81); other associations were weaker or not statistically significant. The association with the homozygous variant was equally strong for squamous cell carcinomas and adenocarcinomas among Caucasians. We analyzed the risk by duration of smoking: for Caucasian subjects with the MspI RFLP combined variants (homozygotes plus heterozygotes), the increase in the risk of lung cancer was steeper than among the individuals with the homozygous reference allele. Our analysis suggests that Caucasians with homozygous variant CYP1A1 polymorphism have a higher risk of lung cancer. The data were more consistent among Caucasians, with a strong association between the homozygous variant in both squamous cell carcinomas and adenocarcinomas, and a stronger association in men than in women. The analyses were more inconsistent and failed to reach statistical significance in Asians. This observation might be due to design specificities or unknown effect modifiers in the Asian studies.

AB - CYP1A1 is involved in the metabolism of benzopyrene, a suspected lung carcinogen; it is therefore conceivable that genetically determined variations in its activity modify individual susceptibility to lung cancer. The role of the CYP1A1 MspI polymorphism in lung cancer has been widely studied but has not been fully clarified. We have included 2,451 cases and 3,358 controls in a pooled analysis of 22 case-control studies on CYP1A1 and lung cancer risk. We found a clear association between the CYP1A1 homozygous MspI restriction fragment length polymorphism (RFLP) and lung cancer risk in Caucasians (age- and gender-adjusted odds ratio = 2.36; 95% confidence interval 1.16-4.81); other associations were weaker or not statistically significant. The association with the homozygous variant was equally strong for squamous cell carcinomas and adenocarcinomas among Caucasians. We analyzed the risk by duration of smoking: for Caucasian subjects with the MspI RFLP combined variants (homozygotes plus heterozygotes), the increase in the risk of lung cancer was steeper than among the individuals with the homozygous reference allele. Our analysis suggests that Caucasians with homozygous variant CYP1A1 polymorphism have a higher risk of lung cancer. The data were more consistent among Caucasians, with a strong association between the homozygous variant in both squamous cell carcinomas and adenocarcinomas, and a stronger association in men than in women. The analyses were more inconsistent and failed to reach statistical significance in Asians. This observation might be due to design specificities or unknown effect modifiers in the Asian studies.

KW - CYP1A1TC polymorphism

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0037400385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037400385&partnerID=8YFLogxK

U2 - 10.1002/ijc.10995

DO - 10.1002/ijc.10995

M3 - Article

C2 - 12594823

AN - SCOPUS:0037400385

VL - 104

SP - 650

EP - 657

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -